Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease.

"Conflict of Interest MV reports lecture fees from Falk, Shire, Lilly, Malesci, Pentax, Olympus, and AstraZeneca. RA has served as a speaker or consultant or received research grants from AbbVie, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Dr Falk Pharma, Ferring, InDex Pharmaceuticals, Janssen-Cilag, MSD Sharp & Dome, Pfizer, Roche Pharma, Samsung Bioepis, Takeda. LP-B reports personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance; grants from Abbvie, MSD, Takeda; stock options: CTMA. GYL is a consultant for Alimentiv. BS has served as consultant for Abbvie, BMS, Boehringer, Celgene, Falk, Janssen, Lilly, Pfizer, Prometheus, Takeda; and has received speaker’s fees from Abbvie, CED Service GmbH, Falk, Ferring, Janssen, Novartis, Pfizer, and Takeda as a representative of Charité – Universitätsmedizin Berlin."

"Funding This work was supported by the Deutsche Forschungsgemeinschaft TRR241 projects INF, A03, C02, C03, and C04 [grant number 375876048]. The Deutsche Forschungsgemeinschaft funds the Heisenberg Professorship of RA [grant number 316866639]."